Additional Listing

6 September 2016

Source BioScience plc(or "the Company")

Additional Listing on Exercise of Share Options

Source BioScience plc (LSE: SBS) announces that it has issued 58,632 new Ordinary Shares of 2 pence each in the Company ("New Ordinary Shares"), following the exercise of share options under the Company's 2001 Approved Share Option Scheme.

Application has been made for the new Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. Admission of the new Ordinary Shares will occur as soon as reasonably practical.

Following the issue and allotment, the Company's issued share capital will comprise 349,351,081 Ordinary Shares of 2 pence each. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, the Company under the FCA's Disclosure and Transparency Rules. The new Ordinary Shares will rank pari passu with existing Ordinary Shares.

Enquiries

Source BioScience plc

Dr Nick Ash, Company Secretary

Tel: +44 (0) 115 973 9010

Email: [email protected]

www.sourcebioscience.com 

About Source BioScience:

Source BioScience plc (LSE: SBS) is a trusted provider of state of the art Laboratory Services and Products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of Laboratory Services and Products that share common technologies, laboratory processes, infrastructure and expertise. These include Diagnostics, DNA Sequencing and Genomics, Analytical and Regulated Services, Clinical Products, Life Science Research Reagents and Controlled Environment for a comprehensive range of applications. These Laboratory Services and Products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.